Mechanistic and translational perspectives on m6A RNA modification in bladder cancer

N6-methyladenosine (m6A) is a reversible and context-dependent RNA modification that links transcript processing to bladder cancer growth, immune escape, treatment response, and tumor-cell plasticity. This review asks three questions: which m6A mechanisms have been experimentally resolved in bladder cancer; how CRISPR systems can establish causal relationships at regulator, transcript, and nucleotide levels; and which targets are sufficiently supported for translational development. We report the experimental settings represented for each axis and assess mechanistic resolution separately; cross-cancer observations are retained only as hypotheses for bladder cancer. Bladder-cancer evidence identifies oncogenic METTL3-centered axes involving AFF4-NF-kB-MYC, ITGA6, pri-miR-221/222-PTEN, RPN2, and PD-L1; an FTO-MALAT1-miR-384-MAL2 axis; YTHDF2-dependent degradation of DDX58/RIG-I; WTAP-NRF2 regulation; and IGF2BP3-mediated stabilization of HMGB1. Reader-resolved axes include METTL3-ITGA6-YTHDF1/3, WTAP-NRF2-YTHDF1, FTO-MALAT1-YTHDF2, YTHDF2-DDX58, IGF2BP3-HSP90AB1, and IGF2BP3-CDK6; METTL3-RPN2-YTHDF1 and METTL3-PD-L1-IGF2BP1 remain reader-implicated because direct reader-target binding was not demonstrated, and RPN2 additionally lacks experimental target-specific m6A mapping. IGF2BP3-HMGB1, YTHDC1-HECW1 and IGF2BP3-PPARγ also remain reader-implicated, with m6A dependence unestablished for HMGB1 and HECW1. No axis has achieved site-resolved validation with site-mutant phenotypic rescue in an immune-competent orthotopic model. METTL14 findings remain directionally inconsistent. Cas9/Cas12a DNA editing, active Cas13 RNA knockdown, and inactive RNA-targeting Cas platforms carrying m6A effectors are treated as distinct technologies. Two bladder-cancer proof-of-concept studies used guide-directed m6A editing: RCas9-METTL3 targeted CDCP1, and a multisite dCasRx-METTL3/ALKBH5 platform targeted ITGA6. These experiments support causal research applications but do not constitute an established therapy. We propose a controlled workflow integrating m6A mapping, genetic perturbation, site-mutant rescue, reader identification, organoids, in vivo models, and therapy-response assays. Detection, biomarker development, pharmacology, delivery, and safety are evaluated with emphasis on analytical validity and the absence of clinical validation for m6A-directed treatment in bladder cancer.